PC-3
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
PC-3 |
Humane Prostata Adenokarzinom (GIV) Zell-Linie |
300312 |
cryovial |
265,00 |
PC-3 |
Humane Prostata Adenokarzinom (GIV) Zell-Linie |
330312 |
vital |
335,00 |
| Designation: | PC-3 |
| Depositor: | Ohnuki |
| Organism: | Homo sapiens (human) |
| Ethnicity: | caucasian |
| Age/Stage: | 62 years |
| Gender: | male |
| Tissue: | prostate; from metastatic site: bone |
| Morphology: | epithelial |
| Celltype: | adenocarcinoma, grade IV |
| Growth Properties: | monolayer; the cells form clusters in soft agar and can be adapted to suspension growth |
| Description: | The cells exhibit low acid phosphatase and testosterone-5- alpha reductase activities. |
| Culture Medium: | Ham's F12K medium supplemented with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 10% fetal bovine serum. |
| Subculturing: | Subcultures are prepared using CTC (Collagenase, 0.01% Trypsin, 0.025% and chick serum, 1%) at room temperature. Alternatively, subcultures can be prepared using a standard trypsin (0.025%) and EDTA (0.03%) dissociation protocol. The initial subculture is done 10 to 14 days after seeding, thereafter |
| Split Ratio: | A ratio of 1:3 to 1:6 is recommended |
| Fluid Renewal: | 2 to 3 times weekly |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice |
| DNA Profile (STR): | Amelogenin: X,X CSF1PO: 11 D13S317: 11 D16S539: 11 D5S818: 13 D7S820: 8,11 THO1: 6,7 TPOX: 8,9 vWA: 17 D3S1358: 16 D21S11: 29,31.2 D18S51: 14,15 Penta E: 10,17 Penta D: 9 D8S1179: 13 FGA: 24 CLS ∙ Cell Lines Service, 2009. |
| Antigen Expression: | HLA A1, A9 |
References: Kaighn ME et al. Prostate carcinoma : tissue culture cell lines. Natl Cancer Inst Monogr 49 : 17-21, 1978. Kaighn ME et al. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979. Ohnuki Y et al. Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res 40: 524-534, 1980. Chen TR. Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. Cytogenet Cell Genet 62: 183-184, 1993. Sheng S et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 93: 11669-74, 1996. Umekita Y et al. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 93: 11802-7, 1996. Carter RE et al. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93: 749-53, 1996. Su ZZ et al. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family. Proc Natl Acad Sci USA 93: 7252-7, 1996. Nupponen NN et al. Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet 101: 53-7, 1998. Geiger T et al. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 13: 35-45, 1998. Zeng Y et al. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 66: 9566-75, 2006. Rantalainen M et al. Statistically integrated metabonomic-prteomic studies on human prostate cancer xenograft model in mice. J Proteome Res 5: 2642-55, 2006. | |
